Stephen H. Petersdorf

powered by
COS Expertise®
University of Washington
School of Medicine
Medicine
Oncology
Associate ProfessorAppointed: 1997
Fred Hutchinson Cancer Research Center
Clinical Research Division
Associate Member
Professional Headshot of Stephen H. Petersdorf

Mailing Address

Box 356043
University of Washington
Seattle, Washington 98195
United States

Contact Information

Phone: (206) 548-4934
Fax: (206) 548-4509
spetersd@u.washington.edu

Qualifications

M.D., Brown University Bio/Med Sciences, 1983.

Keywords

COS Keywords:

Health and Medicine.

Publications

  • Bowen J D, Petersdorf S H, Richards T L, Maravilla K R, Dale D C, Price T H, St. John T P, Yu A S, Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis., Clinical Pharmacology and Therapeutics, 64(3), 339-46, September 1998 Abstract
  • Bensinger W I, Schiffman K S, Holmberg L, Appelbaum F R, Maziarz R, Montgomery P, Ellis E, Rivkin S, Weiden P, Lilleby K, Rowley S, Petersdorf S, Klarnet J P, Nichols W, Hertler A, McCroskey R, Weaver C H, Buckner C D, High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer., Bone Marrow Transplantation, 19(12), 1183-9, June 1997 Abstract
  • Robinson N, Benyunes M C, Thompson J A, York A, Petersdorf S, Press O, Lindgren C, Chauncey T, Buckner C D, Bensinger W I, Appelbaum F R, Fefer A, Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study., Bone Marrow Transplantation, 19(5), 435-42, March 1997 Abstract
  • Schiffman K S, Bensinger W I, Appelbaum F R, Rowley S, Lilleby K, Clift R A, Weaver C H, Demirer T, Sanders J E, Petersdorf S, Gooley T, Weiden P, Zuckerman N, Montgomery P, Maziarz R, Klarnet J P, Rivkin S, Trueblood K, Storb R, Holmberg L, Buckner C D, Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease., Bone Marrow Transplantation, 17(6), 943-50, June 1996 Abstract
  • Cain J M, Collins C, Petersdorf S, Figge D C, Tamimi H K, Greer B E, Livingston R B, Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer., American Journal of Obstetrics and Gynecology, 174(6), 1688-94; discussion, June 1996 Abstract
  • Petersdorf S H, Dale D C, The biology and clinical applications of erythropoietin and the colony-stimulating factors., Advances In Internal Medicine, 40, 395-428, 1995 Abstract
  • Weaver C H, Bensinger W I, Appelbaum F R, Lilleby K, Sandmaier B, Brunvand M, Rowley S, Petersdorf S, Rivkin S, Gooley T, et al, Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies., Bone Marrow Transplantation, 14(5), 813-9, November 1994 Abstract
  • Petersdorf S H, Livingston R B, High dose chemotherapy for the treatment of malignant brain tumors., Journal of Neuro-oncology, 20(2), 155-63, 1994 Abstract
  • Collins C, Eary J F, Donaldson G, Vernon C, Bush N E, Petersdorf S, Livingston R B, Gordon E E, Chapman C R, Appelbaum F R, Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial., Journal of Nuclear Medicine, 34(11), 1839-44, November 1993 Abstract
  • Eary J F, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison S J, Appelbaum F, et al, Samarium-153-EDTMP biodistribution and dosimetry estimation [see comments], Journal of Nuclear Medicine, 34(7), 1031-6, July 1993 Abstract

Profile Details

Last Updated: 10/9/2001

COS Expertise ID #135374
Reference this profile directly: http://myprofile.cos.com/PETERSDORF4